Tyra Biosciences, Inc. (NASDAQ:TYRA) Receives Average Recommendation of “Moderate Buy” from Analysts

Tyra Biosciences, Inc. (NASDAQ:TYRA) has been given an average recommendation of “Moderate Buy” by the six ratings firms that are covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, four have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $34.20.

A number of research firms have weighed in on TYRA. Wall Street Zen upgraded shares of Tyra Biosciences from a “sell” rating to a “hold” rating in a research note on Sunday, January 4th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Tyra Biosciences in a research report on Wednesday, October 8th. Finally, Wedbush increased their price target on shares of Tyra Biosciences from $30.00 to $37.00 and gave the stock an “outperform” rating in a research report on Tuesday, December 16th.

Tyra Biosciences Stock Down 0.9%

TYRA stock opened at $28.77 on Friday. The business’s 50-day simple moving average is $23.21 and its 200 day simple moving average is $16.08. The company has a market cap of $1.54 billion, a PE ratio of -15.38 and a beta of 1.07. Tyra Biosciences has a twelve month low of $6.42 and a twelve month high of $30.70.

Tyra Biosciences (NASDAQ:TYRA) last announced its quarterly earnings data on Wednesday, November 5th. The company reported ($0.50) EPS for the quarter, hitting analysts’ consensus estimates of ($0.50). On average, equities research analysts anticipate that Tyra Biosciences will post -1.57 EPS for the current year.

Insider Activity

In related news, Director Robert J. More sold 246,871 shares of the firm’s stock in a transaction that occurred on Friday, November 21st. The stock was sold at an average price of $20.25, for a total transaction of $4,999,137.75. Following the completion of the transaction, the director owned 3,833,425 shares in the company, valued at $77,626,856.25. This trade represents a 6.05% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 15.20% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Federated Hermes Inc. increased its position in Tyra Biosciences by 586.3% in the 3rd quarter. Federated Hermes Inc. now owns 2,155 shares of the company’s stock valued at $30,000 after acquiring an additional 1,841 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Tyra Biosciences by 14.5% during the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 13,182 shares of the company’s stock valued at $126,000 after purchasing an additional 1,668 shares during the last quarter. SG Americas Securities LLC bought a new stake in shares of Tyra Biosciences during the third quarter valued at approximately $133,000. Public Employees Retirement System of Ohio acquired a new stake in shares of Tyra Biosciences in the 2nd quarter valued at $177,000. Finally, Russell Investments Group Ltd. increased its position in Tyra Biosciences by 27.7% in the third quarter. Russell Investments Group Ltd. now owns 12,741 shares of the company’s stock worth $178,000 after purchasing an additional 2,766 shares during the period. 84.14% of the stock is currently owned by institutional investors and hedge funds.

Tyra Biosciences Company Profile

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.